Trastuzumab as an anti-HER2 monoclonal antibody deactivates the downstream pathways and inhibits the production of HER2 dimers, which results in the suppression of tumor growth while apoptosis induction [82]. The gene discussed is ERBB2; the disease is neoplasm.